ID: ALA2426568

Max Phase: Preclinical

Molecular Formula: C18H21N5O2S2

Molecular Weight: 403.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCc1sc(-c2ccc(OC)c(O)c2)nc1CSc1nc(N)cc(N)n1

Standard InChI:  InChI=1S/C18H21N5O2S2/c1-3-4-14-11(9-26-18-22-15(19)8-16(20)23-18)21-17(27-14)10-5-6-13(25-2)12(24)7-10/h5-8,24H,3-4,9H2,1-2H3,(H4,19,20,22,23)

Standard InChI Key:  UFTDEMPMKXDHOK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.53

Molecular Weight (Monoisotopic): 403.1137

AlogP: 3.72

#Rotatable Bonds: 7

Polar Surface Area: 120.17

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.46

CX Basic pKa: 7.74

CX LogP: 3.99

CX LogD: 3.64

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.40

Np Likeness Score: -0.92

References

1. Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG..  (2013)  Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.,  56  (17): [PMID:23947754] [10.1021/jm400457y]

2. Nomme J, Li Z, Gipson RM, Wang J, Armijo AL, Le T, Poddar S, Smith T, Santarsiero BD, Nguyen HA, Czernin J, Alexandrova AN, Jung ME, Radu CG, Lavie A..  (2014)  Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.,  57  (22): [PMID:25341194] [10.1021/jm501124j]

Source

Source(1):

• Scientific Literature